SITC Annual Meeting 2026: key results and trends
What the 1,128 abstracts at SITC Annual Meeting 2026 reported, drug by drug: the readouts that stood out and the targets and modalities that dominated, and how this edition compares with earlier years.
- abstracts
- 1,128
- 12% fewer than 2025
- drug-linked abstracts
- 647
- companies
- 272
- from Phase 3 studies
- 7
Drug-linked abstracts by phase
- Phase 1 76
- Phase 1/2 31
- Phase 2 41
- Phase 2/3 2
- Phase 3 7
Key results
Quotes are taken verbatim from each abstract's results; selection is automated. Report an issue
QL2107
539 A randomized, double-blind, phase III trial to compare SB27 (a proposed biosimilar to pembrolizumab) to reference pembrolizumab in participants with metastatic non-squamous non-small cell lung cancer
Read the abstract (opens in a new tab)ORR at Week 24 was 34.6% in SB27 and 37.9% in Pembro; the ORR ratio was 0.89 and its 90% CI was (0.737, 1.071), which was within the pre-defined margin (FAS).
nogapendekin alfa inbakicept
496 Nogapendekin alfa inbakicept (NAI), an IL-15R agonist, prolongs OS in solid tumors after standard-of-care and checkpoint inhibitor (CPI) failure: updated results from QUILT-3.055
Read the abstract (opens in a new tab)Across all tumor types, mOS was 14.3 (95% CI: 12.2-16.9) and 15.8 versus 11.8 months in ALC responders (mean ALC ≥1,000 cells/µL) versus non-responders (hazard ratio [HR] 0.59; P = 0.0281).
lifileucel
335 Long-term durable efficacy of lifileucel one-time treatment: post-hoc landmark analysis of overall survival by response in advanced melanoma patients (C-144-01 study)
Read the abstract (opens in a new tab)Notably, 21 of 28 (75%) 5-year completers (7 CR, 11 PR, 3 SD) remained alive and treatment-free (no new anticancer therapy) with OS of 55.0 to 61.7 months after a single lifileucel infusion.
IDP-023
1185 IDP-023 allogeneic g-NK cells combined with isatuximab in relapse/refractory multiple myeloma: complete safety, efficacy, and tumor microenvironment remodeling from a Phase 1/2 first-in-human study
Read the abstract (opens in a new tab)Of 11 efficacy-evaluable IDP-023 + isatuximab patients, overall-response-rate (ORR) was 36% (4/11) and clinical-benefit-rate (CBR) 55% (6/11), versus 0%/3% expected for isatuximab alone in CD38-refractory disease.
MDNA11
517 MDNA11 demonstrates clinical activity as monotherapy and in combination with pembrolizumab in biomarker-enriched gastrointestinal malignancies, including ICI-refractory disease
Read the abstract (opens in a new tab)MDNA11 plus pembrolizumab demonstrated an ORR of 57% (4/7; 95% CI: 18–90), including 1 unconfirmed response (lost to follow-up), and a DCR of 86% (6/7; 95% CI: 42–100).
imneskibart
611 Imneskibart + low-dose subcutaneous IL-2 ± nivolumab in doublet checkpoint inhibitor-refractory melanoma: promising activity in an ongoing phase 1/2 study
Read the abstract (opens in a new tab)Imneskibart + IL-2 was well tolerated with Grade 3/4 drug-related adverse events occurring in 14.5 % of pts and in 10.5% of pts who received the combination with nivolumab.
brenetafusp
1177 Phase 1 evaluation of brenetafusp alone and in combination with tebentafusp in metastatic uveal melanoma
Read the abstract (opens in a new tab)Among 1L mUM patients (n = 17), tebentafusp + brenetafusp treatment was associated with favorable efficacy outcomes with 29% ORR, 24.1-month median DOR, 8.1-month median PFS, 88% 1-yr OS, and 70% 2-yr OS.
an4005
563 Updated safety and efficacy of AN4005, an oral small-molecule PD-L1 inhibitor, in advanced solid tumors: phase I dose-escalation and expansion
Read the abstract (opens in a new tab)Rash was more frequent in Part 3 than in Parts 1–2 (48% vs 2.9%) and had an early onset (median = 10 days), with most events manageable.ss In ASPS (Cohort 3A), ORR was 15% and the DCR was 60%; median duration of response was not reached.
SER-155
534 High immunosuppressive-free response rate of immune checkpoint inhibitor (ICI)-related enterocolitis with SER-155, an investigational oral live biotherapeutic, in a phase 1b study
Read the abstract (opens in a new tab)Two participants (13%) experienced a serious TEAE, neither attributed to SER-155.
Trends at SITC 2026
Monoclonal antibodies, the most frequent modality, accounted for 28% of drug-linked abstracts, up from 22% in 2025. Small molecules accounted for 23% of drug-linked abstracts, up from 19% in 2025. CD28 (2%) was new to the top targets compared with 2025.
What the abstracts covered
Share of the 647 drug-linked abstracts, by the target, modality, disease and company of each drug. An abstract can count in more than one row, so a list can add up to more than 100%.
- Antibody-drug conjugates5%35 drug-linked abstracts · level with 4% in 2025
- Bispecific antibodies13%87 drug-linked abstracts · level with 12% in 2025
Top targets
- PDCD18313% from 11% in 2025
- CD3467%
- CD274386% from 4% in 2025
- CD19284% from 6% in 2025
- IL2RB152%
- VEGFA152%
- CTLA-4142%
- B7-H3132%
- IL-12R132%
- CD28New122%
Top modalities
- Monoclonal antibodies18128% from 22% in 2025
- Small molecules15223% from 19% in 2025
- Cell therapies14623%
- Bispecific antibodies8713%
- Non-antibody therapeutic proteins7612% from 10% in 2025
- Oligonucleotide and RNA therapeutics376%
- Vaccines376% from 8% in 2025
- Gene therapies366%
Top diseases
- Melanoma12419%
- Colorectal cancer (CRC)8113%
- Non-small cell lung cancer (NSCLC)7011%
- Breast cancer498%
- Ovarian cancer376%
- Triple-negative breast cancer (TNBC)294%
- Glioblastoma (GBM)264%
- Pancreatic cancer (PC)254%
- Pancreatic adenocarcinoma (PDAC)244%
- Head and neck squamous cell carcinoma (HNSCC)234%
Most active companies
- Bristol Myers Squibb386%
- Merck335%
- AstraZeneca142%
- Genentech142%
- Amgen122%
- Novartis122%
- Iovance Biotherapeutics102%
- Pfizer102%
- Eli Lilly81%
- Johnson & Johnson71%
SITC over the years
- 20261,128 abstracts · this edition
- 20251,283 abstracts
Explore every SITC 2026 result in Gosset
All 647 drug-linked abstracts, joined to each drug’s trials, targets, developers and deals, with a source behind every line.
This page shows a sample of results. Gosset has the abstracts from this meeting and 100+ others; reach out for full access.